In the past, there was much concern about whether GH therapy might increase cancer risk, but it has now been established that GH treatment does not increase the rate of tumor recurrence in patients previously treated for primary CNS lesions [2,3], and recent guidelines recommend starting GH therapy a year after the end of the oncological treatment if there is no evidence for further tumor growth. Here, GH1 is linked to neoplasm.